Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction
- PMID: 32883680
- DOI: 10.1183/13993003.00839-2020
Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction
Abstract
Oxidised phosphatidylcholines (OxPCs) are produced under conditions of elevated oxidative stress and can contribute to human disease pathobiology. However, their role in allergic asthma is unexplored. The aim of this study was to characterise the OxPC profile in the airways after allergen challenge of people with airway hyperresponsiveness (AHR) or mild asthma. The capacity of OxPCs to contribute to pathobiology associated with asthma was also to be determined.Using bronchoalveolar lavage fluid from two human cohorts, OxPC species were quantified using ultra-high performance liquid chromatography-tandem mass spectrometry. Murine thin-cut lung slices were used to measure airway narrowing caused by OxPCs. Human airway smooth muscle (HASM) cells were exposed to OxPCs to assess concentration-associated changes in inflammatory phenotype and activation of signalling networks.OxPC profiles in the airways were different between people with and without AHR and correlated with methacholine responsiveness. Exposing patients with mild asthma to allergens produced unique OxPC signatures that associated with the severity of the late asthma response. OxPCs dose-dependently induced 15% airway narrowing in murine thin-cut lung slices. In HASM cells, OxPCs dose-dependently increased the biosynthesis of cyclooxygenase-2, interleukin (IL)-6, IL-8, granulocyte-macrophage colony-stimulating factor and the production of oxylipins via protein kinase C-dependent pathways.Data from human cohorts and primary HASM cell culture show that OxPCs are present in the airways, increase after allergen challenge and correlate with metrics of airway dysfunction. Furthermore, OxPCs may contribute to asthma pathobiology by promoting airway narrowing and inducing a pro-inflammatory phenotype and contraction of airway smooth muscle. OxPCs represent a potential novel target for treating oxidative stress-associated pathobiology in asthma.
Copyright ©ERS 2021.
Conflict of interest statement
Conflict of interest: C.D. Pascoe has nothing to disclose. Conflict of interest: A. Jha has nothing to disclose. Conflict of interest: M.H. Ryu has nothing to disclose. Conflict of interest: M. Ragheb has nothing to disclose. Conflict of interest: J. Vaghasiya has nothing to disclose. Conflict of interest: S. Basu has nothing to disclose. Conflict of interest: G.L. Stelmack has nothing to disclose. Conflict of interest: S. Srinathan has nothing to disclose. Conflict of interest: B. Kidane has nothing to disclose. Conflict of interest: J. Kindrachuk has nothing to disclose. Conflict of interest: P.M. O'Byrne has received consulting and/or speakers fees from AstraZeneca, GSK, Chiesi and Meranari, and grants in aid from AstraZeneca, Medimmune, GSK, Novartis and Merck, outside the submitted work. Conflict of interest: G.M. Gauvreau has nothing to disclose. Conflict of interest: A. Ravandi has nothing to disclose. Conflict of interest: C. Carlsten has nothing to disclose. Conflict of interest: A.J. Halayko has nothing to disclose.
Comment in
-
Honing in on the effectors of oxidative stress in the asthmatic lung: oxidised phosphatidylcholines.Eur Respir J. 2021 Feb 17;57(2):2003736. doi: 10.1183/13993003.03736-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 33602878 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials